Nab-paclitaxel Versus Solvent-based Taxanes As First-Line Treatment for Patients With Advanced Ovarian Cancer

What this Trial Is About

Researchers are evaluating the safety and effectiveness of nab-paclitaxel compared to solvent-based taxanes as first-line treatments for patients with advanced primary epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma. This Phase 3 study aims to address challenges such as high rates of allergic reactions seen with solvent-based taxanes and explores whether nab-paclitaxel can be a feasible initial treatment option for these cancers. The study compares two main treatment groups: one receives nab-paclitaxel combined with carboplatin either every three weeks or weekly for six cycles, and the other receives paclitaxel combined with carboplatin in similar dosing schedules. Treatments are given intravenously with specific doses and timing, repeated every 21 days over 18 weeks in total. Both groups undergo systemic therapy after surgery if applicable. Participants will have regular clinical visits for treatment administration and monitoring. Researchers will assess outcomes such as progression-free survival over 20 months, remission rates at 12 months, overall survival at 3 and 5 years, and adverse events during these periods. The study includes various evaluations like physical condition, tumor response, and safety checks to track participant health and treatment effects throughout the trial duration.

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer